The Claim
The increase in selenoprotein P following high-dose intravenous selenite is independent of patient age and sex in critically ill populations.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In critically ill patients, high-dose intravenous selenite raises selenoprotein P levels regardless of the patient's age or sex.
See the scientific wording
The increase in selenoprotein P following high-dose intravenous selenite is independent of patient age and sex, suggesting that SELENOP response to selenium overload is not modulated by these demographic factors in critically ill populations.
When high doses of selenium are given intravenously, the body converts it into a usable form that liver cells use to make more of a protein called selenoprotein P. The liver keeps making more of this protein even when levels are already high, and releases it into the blood to carry selenium to other parts of the body. This process happens the same way in all patients, no matter their age or sex.
What the research says
1 studyIn very sick patients given high-dose selenium through an IV, both men and women, young and old, had similar increases in a protein called SELENOP — meaning age and sex didn’t change how their bodies responded.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.